Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD traded up $0.39 during mid-day trading on Friday, reaching $11.87. 3,535,618 shares of the stock traded hands, compared to its average volume of 2,471,710. The firm has a fifty day moving average price of $11.64 and a 200 day moving average price of $11.65. The company has a market cap of $1.83 billion, a price-to-earnings ratio of 11.75 and a beta of 1.04. The company has a current ratio of 26.52, a quick ratio of 4.82 and a debt-to-equity ratio of 0.74. Ironwood Pharmaceuticals has a 1 year low of $10.13 and a 1 year high of $14.27.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Rating) last announced its earnings results on Thursday, August 4th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.10). Ironwood Pharmaceuticals had a return on equity of 31.01% and a net margin of 41.65%. The company had revenue of $97.23 million during the quarter, compared to analysts' expectations of $103.51 million. During the same quarter last year, the firm posted $0.34 earnings per share. The firm's revenue was down 6.5% on a year-over-year basis. As a group, equities research analysts predict that Ironwood Pharmaceuticals will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

IRWD has been the subject of a number of recent analyst reports. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Wednesday, June 15th. Piper Sandler initiated coverage on shares of Ironwood Pharmaceuticals in a research report on Friday, April 22nd. They set an "overweight" rating and a $16.00 price target for the company.

Insider Buying and Selling

In related news, CEO Thomas A. Mccourt sold 23,229 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $11.35, for a total value of $263,649.15. Following the completion of the transaction, the chief executive officer now directly owns 757,785 shares in the company, valued at $8,600,859.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 23,229 shares of the business's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $11.35, for a total value of $263,649.15. Following the completion of the sale, the chief executive officer now directly owns 757,785 shares of the company's stock, valued at $8,600,859.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas A. Mccourt sold 36,308 shares of the business's stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $11.50, for a total transaction of $417,542.00. Following the completion of the sale, the chief executive officer now directly owns 798,881 shares of the company's stock, valued at $9,187,131.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 277,489 shares of company stock worth $3,287,473. Corporate insiders own 13.10% of the company's stock.